INTRODUCTION {#s1}
============

Liver cancer is the second leading cause of cancer-related death among men worldwide. There were an estimated 782,500 new liver cancer cases and 745,500 liver cancer-related deaths in 2012 worldwide. China alone accounted for approximately 50% of the total number of cases and deaths \[[@R1]\]. Liver cancer is a complex and multifactorial disease regulated by both genetic and environmental factors. Epidemiological studies have shown that the major environmental risk factors for liver cancer include chronic Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infection, dietary aflatoxin exposure, alcohol consumption, cigarette smoking, obesity, diabetes, and iron overload \[[@R2], [@R3]\]. However, not all individuals with exposure to these risk factors develop liver cancer. Hepatocellular carcinoma (HCC) accounts for between 70% and 85% of primary liver cancers. Recently, some Genome-wide association studies (GWAS) have identified several loci associated with the risk of HCC, such as SNPs in the gene *KIF1B*, *MICA*, *HLA-DQA/DQB*, and *GRIK1*, respectively \[[@R4]--[@R6]\].

Acylphosphatase 2 (*ACYP2*) encodes a small cytosolic enzyme (11 kDa) that is widely expressed in vertebrates. Two isoenzymes have been identified (muscle and erythrocyte) that share 56% sequence identity \[[@R7]\]. *ACYP2* hydrolyzes the phosphoenzyme intermediate of various membrane pumps such as the Ca^2+^/Mg^2+^-ATPase from the sarcoplasmic reticulum of skeletal muscle \[[@R8]\]. Overexpression of *ACYP2* induces cell differentiation \[[@R9]\] and apoptosis \[[@R10]\]. In addition, a genome wide association study demonstrated an association between *ACYP2* polymorphisms and telomere length \[[@R11]\].

Interestingly, telomere length was also correlated with risk of liver cancer \[[@R12], [@R13]\]. However, a direct association between single nucleotide polymorphisms (SNPs) in *ACYP2* and susceptibility to liver cancer has not been established. We hypothesized that genetic variations in *ACYP2* could influence susceptibility to liver cancer. We selected 13 SNPs from the HapMap databases with a minor allele frequency (MAF) \> 5% in the Chinese Han population, and designed a case-control study to investigate the associations between these SNPs and the risk of liver cancer.

RESULTS {#s2}
=======

Study population {#s2_1}
----------------

The characteristics of all study participants are shown in Table [1](#T1){ref-type="table"}. There were 473 liver cancer patients (390 men and 83 women) and 564 healthy controls (339 men and 225 women) included in the study. The average ages of the cases and controls were 55.8 and 53.9 years, respectively. There were significant differences in the age and gender distribution between the cases and controls (*P* \< 0.05) (Table [1](#T1){ref-type="table"}). Therefore, we adjusted for these variables in the multivariate, unconditional logistic regression.

###### Characteristics of the cases and controls

  Variables         Cases (*n* = 473)   Controls (*n* = 564)   *P*
  ----------------- ------------------- ---------------------- --------------
  Sex                                                          **\< 0.001**
  Male              390 (82.5%)         339 (60.1%)            
  Female            83 (17.5%)          225 (39.9%)            
  Age                                                          **0.010**
  yrs (mean ± SD)   55.8 ± 12.2         53.9 ± 11.5            

SD: Standard deviation.

*P* \< 0.05 indicates statistical significance.

The sequences of the primers that were used to genotype each SNP are shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. The average SNP call rate was 98.3% in cases and controls. The allele distributions and MAFs of all SNPs and the results of Hardy-Weinberg equilibrium (HWE) tests are shown in Table [2](#T2){ref-type="table"}. The genotype distributions of the 13 SNPs among the controls were compatible with HWE (all *P* \> 0.05). The G allele of rs6713088, T allele of rs843711, and A allele of rs843706 were associated with a 1.27-fold, 1.29-fold, and 1.30-fold increased risk of liver cancer, respectively (odds ratio \[OR\] = 1.27, 95% confidence interval \[CI\]: 1.07--1.52, *P* = 0.007; OR = 1.29, 95% CI: 1.09--1.54, *P* = 0.004; OR = 1.30, 95% CI: 1.09--1.55, *P* = 0.003, respectively). In contrast, the A allele of rs1682111 was associated with a decreased risk of liver cancer (OR = 0.77, 95% CI: 0.64--0.94, *P* = 0.007). However, no significant association between SNPs in *ACYP2* and liver cancer risk was observed after Bonferroni correction.

###### Allele frequencies distribution and association with the risk of liver cancer

  SNP-ID       Chromosome   Position   Band     Role         Allele (A/B)   MAF     HWE *P*^a^   OR      95% CI   *P*^b^       
  ------------ ------------ ---------- -------- ------------ -------------- ------- ------------ ------- -------- ------------ -------
  rs6713088    2            54345469   2p16.2   Intron       G/C            0.452   0.393        0.379   1.27     1.07--1.52   0.007
  rs12621038   2            54391113   2p16.2   Intron       T/C            0.445   0.440        0.608   1.02     0.86--1.22   0.813
  rs1682111    2            54427979   2p16.2   Intron       A/T            0.275   0.329        0.775   0.77     0.64--0.94   0.008
  rs843752     2            54446587   2p16.2   Intron       G/T            0.296   0.266        0.518   1.16     0.95--1.40   0.142
  rs10439478   2            54459450   2p16.2   Intron       C/A            0.427   0.402        0.382   1.11     0.93--1.32   0.258
  rs17045754   2            54496757   2p16.2   Intron       C/G            0.197   0.167        0.761   1.22     0.98--1.53   0.077
  rs843720     2            54510660   2p16.2   Intron       G/T            0.303   0.342        0.779   0.84     0.69--1.01   0.057
  rs843645     2            54474664   2p16.2   Downstream   G/T            0.282   0.252        0.263   1.17     0.96--1.42   0.116
  rs11125529   2            54475866   2p16.2   Downstream   A/C            0.185   0.164        0.644   1.16     0.92--1.46   0.201
  rs12615793   2            54475914   2p16.2   Downstream   A/G            0.201   0.178        0.315   1.16     0.93--1.45   0.181
  rs843711     2            54479117   2p16.2   Downstream   T/C            0.501   0.437        1.000   1.29     1.09--1.54   0.004
  rs11896604   2            54479199   2p16.2   Downstream   G/C            0.214   0.185        0.675   1.20     0.97--1.49   0.098
  rs843706     2            54480369   2p16.2   3′ UTR       A/C            0.504   0.439        1.000   1.30     1.09--1.55   0.003

*P*^a^-values were calculated using Fisher\'s exact test.

*P*^b^-values were calculated using Pearson\'s chi-square test.

*P* \< 0.05 indicates statistical significance.

Significant associations between *ACPY2* genotypes and the risk of liver cancer are shown in Table [3](#T3){ref-type="table"}. We found that rs6713088, rs843645, rs843711, and rs843706 were associated with an increased risk of liver cancer even after adjustment for age and gender (GG vs. CC: OR = 1.49, 95% CI: 1.02--2.1, *P* = 0.038; GT vs. TT: OR = 1.40, 95% CI: 1.07--1.82, *P* = 0.014; TT vs. CC: OR = 1.62, 95% CI: 1.13--2.31, *P* = 0.008; AA vs. CC: OR = 1.62, 95% CI: 1.13--2.31, *P* = 0.008, respectively). In contrast, the AT genotype of rs1682111 was associated with a decreased risk of liver cancer compared to the TT genotype (OR = 0.69, 95% CI: 0.53--0.91, *P* = 0.007, respectively). Interestingly, the AA genotype of rs1682111 was also associated with a decreased risk of liver cancer compared to the TT genotype after adjustment for age and gender (OR = 0.62, 95% CI: 0.39--0.98, *P* = 0.039). We also found that the GG genotype of rs843720 was associated with a decreased risk of liver cancer compared to the TT genotype without adjustment for age and gender (OR = 0.64, 95% CI: 0.41--1.00, *P* = 0.048).

###### Genotype frequencies distribution and association with liver risk cancer

  SNP-ID       Genotype   Cases   Controls   Without adjustment   With adjustment                                   
  ------------ ---------- ------- ---------- -------------------- ----------------- ----------- ------ ------------ -----------
               CC         138     202        1.00                 --                            1.00   --           
  rs6713088    GC         242     279        1.27                 0.96--1.67        0.091       1.27   0.95--1.69   0.100
               GG         93      82         1.66                 1.15--2.40        **0.007**   1.49   1.02--2.18   **0.038**
               CC         139     180        1.00                 --                            1.00   --           
  rs12621038   TC         245     271        1.17                 0.88--1.55        0.271       1.28   0.96--1.71   0.098
               TT         87      112        1.01                 0.70--1.44        0.974       1.08   0.75--1.56   0.685
               TT         251     252        1.00                 --                            1.00   --           
  rs1682111    AT         181     253        0.72                 0.55--0.93        **0.012**   0.69   0.53--0.91   **0.007**
               AA         39      59         0.66                 0.43--1.03        0.068       0.62   0.39--0.98   **0.039**
               TT         232     306        1.00                 --                            1.00   --           
  rs843752     GT         201     214        1.24                 0.96--1.60        0.103       1.23   0.94--1.61   0.127
               GG         39      43         1.20                 0.75--1.91        0.451       1.13   0.70--1.83   0.612
               AA         154     206        1.00                 --                --          1.00   --           --
  rs10439478   CA         233     261        1.19                 0.91--1.57        0.204       1.20   0.91--1.60   0.201
               CC         85      96         1.18                 0.83--1.70        0.355       1.31   0.90--1.90   0.162
               GG         302     390        1.00                 --                --          1.00   --           --
  rs17045754   CG         156     160        1.26                 0.96--1.64        0.091       1.27   0.96--1.67   0.095
               CC         15      14         1.38                 0.66--2.91        0.392       1.37   0.63--2.97   0.421
               TT         224     242        1.00                 --                --          1.00   --           --
  rs843720     GT         210     258        0.88                 0.68--1.14        0.327       0.85   0.65--1.11   0.243
               GG         38      64         0.64                 0.41--1.00        **0.048**   0.64   0.41--1.01   0.057
               TT         235     321        1.00                 --                --          1.00   --           --
  rs843645     GT         206     202        1.39                 1.08--1.80        **0.011**   1.40   1.07--1.82   **0.014**
               GG         30      41         1.00                 0.61--1.65        0.998       0.96   0.57--1.60   0.868
               CC         310     392        1.00                 --                --          1.00   --           --
  rs11125529   AC         149     159        1.19                 0.91--1.55        0.216       1.20   0.91--1.58   0.204
               AA         13      13         1.27                 0.58--2.77        0.557       1.16   0.52--2.60   0.718
               GG         297     377        1.00                 --                            1.00   --           
  rs12615793   AG         160     173        1.17                 0.90--1.53        0.233       1.18   0.90--1.55   0.243
               AA         15      14         1.36                 0.65--2.86        0.418       1.21   0.56--2.60   0.630
               CC         126     178        1.00                 --                            1.00   --           
  rs843711     TC         218     278        1.11                 0.83--1.48        0.488       1.13   0.84--1.52   0.426
               TT         127     107        1.68                 1.19--2.37        **0.003**   1.62   1.13--2.31   **0.008**
               CC         288     376        1.00                 --                            1.00   --           
  rs11896604   GC         164     167        1.28                 0.98--1.67        0.066       1.32   1.00--1.73   0.050
               GG         19      21         1.18                 0.62--2.24        0.610       1.08   0.56--2.08   0.824
               CC         124     177        1.00                 --                            1.00   --           
  rs843706     AC         219     277        1.13                 0.84--1.51        0.414       1.14   0.84--1.53   0.404
               AA         128     108        1.69                 1.20--2.39        **0.003**   1.62   1.13--2.31   **0.008**

*P*-values were calculated using the Wald test.

*P* \< 0.05 indicates statistical significance.

The results of genetic model analyses (dominant, recessive, and additive) after adjustment for age and gender are presented in Table [4](#T4){ref-type="table"}. We found that rs6713088 was associated with a 1.32-fold and 1.23-fold increased risk of liver cancer under the dominant model (OR = 1.32, 95% CI: 1.01--1.74, *P* = 0.043) and additive model (OR = 1.23, 95% CI: 1.02--1.48, *P* = 0.028), respectively. Additionally, rs843645 was associated with an increased risk of liver cancer under the dominant model (OR = 1.32, 95% CI: 1.02--1.70, *P* = 0.033). Rs843711 and rs843706 were associated with an increased risk of liver cancer under the recessive model (OR = 1.50, 95% CI: 1.11--2.03, *P* = 0.009; OR = 1.49, 95% CI: 1.10--2.02, *P* = 0.009, respectively) and additive model (OR = 1.26, 95% CI: 1.06--1.51, *P* = 0.010; OR = 1.26, 95% CI: 1.06--1.51, *P* = 0.010, respectively). In contrast, rs1682111 was associated with a decreased risk of liver cancer under both the dominant and additive model (OR = 0.68, 95% CI: 0.53--0.88, *P* = 0.003; OR = 0.75, 95% CI: 0.61--0.91, *P* = 0.004, respectively). Finally, rs843720 was associated with a decreased risk of liver cancer under the additive model (OR = 0.82, 95% CI: 0.68--1.00, *P* = 0.049).

###### Genetic model analyses of the association between SNPs in *ACPY2* and the risk of liver cancer

  SNP-ID       Dominant   Recessive    Additive                                                        
  ------------ ---------- ------------ ----------- ------ ------------ ----------- ------ ------------ -----------
  rs6713088    1.32       1.01--1.74   **0.043**   1.29   0.92--1.81   0.138       1.23   1.02--1.48   **0.028**
  rs12621038   1.22       0.93--1.61   0.158       0.93   0.67--1.28   0.646       1.06   0.80--1.28   0.499
  rs1682111    0.68       0.53--0.88   **0.003**   0.73   0.47--1.14   0.168       0.75   0.61--0.91   **0.004**
  rs843752     1.21       0.94--1.56   0.135       1.03   0.65--1.65   0.886       1.13   0.93--1.38   0.218
  rs10439478   1.23       0.94--1.61   0.130       1.17   0.84--1.64   0.351       1.15   0.96--1.38   0.125
  rs17045754   1.28       0.97--1.67   0.077       1.27   0.59--2.74   0.536       1.24   0.97--1.57   0.080
  rs843720     0.81       0.63--1.05   0.109       0.70   0.45--1.08   0.103       0.82   0.68--1.00   **0.049**
  rs843645     1.32       1.02--1.70   **0.033**   0.83   0.50--1.37   0.471       1.16   0.94--1.42   0.158
  rs11125529   1.20       0.91--1.57   0.197       1.10   0.49--2.45   0.818       1.16   0.91--1.48   0.226
  rs12615793   1.18       0.90--1.54   0.224       1.15   0.53--2.45   0.728       1.15   0.91--1.46   0.238
  rs843711     1.27       0.96--1.68   0.095       1.50   1.11--2.03   **0.009**   1.26   1.06--1.51   **0.010**
  rs11896604   1.29       0.99--1.68   0.061       0.98   0.51--1.89   0.960       1.20   0.96--1.50   0.115
  rs843706     1.28       0.96--1.69   0.090       1.49   1.10--2.02   **0.009**   1.26   1.06--1.51   **0.010**

*P*-values were calculated using the Wald test with adjustment for age and gender.

*P* \< 0.05 indicates statistical significance.

We next analyzed the association between *ACYP2* haplotypes and the risk of liver cancer. We identified one linkage disequilibrium (LD) block consisting of eight SNPs (rs1682111, rs843752, rs10439478, rs843645, rs11125529, rs12615793, rs843711, and rs11896604). A second block consisting of two SNPs (rs843706 and rs17045754) also exhibited strong LD as shown in Figure [1](#F1){ref-type="fig"}. The ATATCGCC and CG haplotypes were associated with a decreased risk of liver cancer (OR = 0.76, 95% CI: 0.62--0.92, *P* = 0.006; OR = 0.78, 95% CI: 0.65--0.93, *P* = 0.006, respectively) (Table [5](#T5){ref-type="table"}).

![Linkage disequilibrium analysis of the 13 SNPs in *ACYP2*\
Block 1 includes rs1682111, rs843752, rs10439478, rs843645, rs11125529, rs12615793, rs843711, and rs11896604. Block 2 includes rs843706 and rs17045754.](oncotarget-08-67723-g001){#F1}

###### Association between *ACYP2* haplotypes and the risk of liver cancer

  -------------------------------------------------------------------------------------------------------------------
  SNPs           Haplotype   Without adjustment   With adjustment                                         
  -------------- ----------- -------------------- ----------------- ----------- ------------ ------------ -----------
  rs1682111/\    ATATCGCC    0.78                 0.64--0.94        **0.010**   0.76         0.62--0.92   **0.006**
  rs843752/\                                                                                              
  rs10439478/\                                                                                            
  rs843645/\                                                                                              
  rs11125529/\                                                                                            
  rs12615793/\                                                                                            
  rs843711/\                                                                                              
  rs11896604                                                                                              

  TTCTAATG       1.18        0.94--1.49           0.160             1.18        0.93--1.51   0.176        

  TGAGCGTC       1.14        0.93--1.39           0.204             1.12        0.91--1.38   0.288        

  TTCTCGCC       0.95        0.76--1.18           0.641             1.02        0.81--1.28   0.851        

  TTCTCGTG       1.21        0.55--2.63           0.636             1.19        0.53--2.67   0.677        

  TTCTCACC       0.9         0.43--1.88           0.789             0.81        0.38--1.72   0.587        

  rs843706/\     AC          1.21                 0.96--1.53        0.100       1.22         0.96--1.55   0.107
  rs17045754                                                                                              

  AG             1.21        1.00--1.46           0.055             1.17        0.96--1.43   0.115        

  CG             0.76        0.64--0.91           **0.002**         0.78        0.65--0.93   **0.006**    
  -------------------------------------------------------------------------------------------------------------------

*P*-values were calculated using the Wald test.

*P* \< 0.05 indicates statistical significance.

DISCUSSION {#s3}
==========

We evaluated the relationships between 13 SNPs in *ACYP2* and the risk of liver cancer in a Han Chinese population. Our results indicated that rs6713088, rs843645, rs843711, and rs843706 were associated with an increased risk of liver cancer. In contrast, rs1682111, rs843720, the ATATCGCC haplotype (rs1682111, rs843752, rs10439478, rs843645, rs11125529, rs12615793, rs843711, and rs11896604), and the CG haplotype (rs843706 and rs17045754) were associated with a decreased risk of liver cancer.

We did not observe an association between rs11125529 and the risk of liver cancer. Previous studies have investigated the association between rs11125529 and coronary heart disease (CHD) \[[@R14]\], gastric cancer \[[@R15]\], high-altitude pulmonary edema (HAPE) \[[@R16]\], glioma \[[@R17]\], and head and neck squamous cell carcinoma \[[@R18]\]. However, no significant associations have been detected. Rs11125529 was associated with a decreased risk of breast cancer in a Han Chinese population based on a genotype model (AC vs. CC) \[[@R19]\], but it was associated with an increased risk of ischemic stroke \[[@R20]\]. A recent genome-wide meta-analysis found that rs11125529 in *ACYP2* was associated with telomere length \[[@R11]\]. Telomeres are critical for maintaining chromosomal stability and integrity \[[@R21]--[@R23]\]. They are approximately 10--15kb in human somatic cells and become progressively shorter by approximately 30--200 bp with each round of cell division as a result of incomplete DNA replication at the 3′ ends of chromosomes \[[@R24]\]. A reduction in telomere length to a critical threshold can lead to double-strand breaks, cell senescence, or apoptosis, which can accelerate human aging and death \[[@R21], [@R25]\]. Telomere length has been implicated in the development of multiple cancers, including hepatocellular carcinoma \[[@R12]\], lung \[[@R26]\], breast \[[@R27]\], bladder \[[@R28]\], and gastric \[[@R29]\], and so on.

We found that rs843711 and rs843706 were associated with an increased risk of liver cancer. rs843711 was reported previously associated with an increased risk of ischemic stroke \[[@R20]\], and similar results were obtained for rs843706, it was observed to be associated with an increased risk of breast cancer in a Han Chinese population \[[@R19]\]. In the study, no association was observed between the four SNPs (rs12621038, rs17045754, rs12615793, and rs11896604) and the risk of liver cancer. However, previous studies have demonstrated that rs12621038 and rs17045754 were associated with a decreased risk of breast cancer \[[@R30]\], but rs17045754 was found associated with an increased risk of ischemic stroke \[[@R20]\]. Rs12615793 and rs11896604 were discovered that them were associated with a decreased risk of HAPE \[[@R16]\], but the two SNPs were reported previously associated with an increased risk of ischemic stroke \[[@R20]\]. In addition, rs11896604 was reported previously associated with a decreased risk of breast cancer \[[@R19]\]. We found that rs6713088 was associated with an increased risk of liver cancer in the present study, and it was associated with an increased risk of ischemic stroke in a Han Chinese Population \[[@R20]\]. Simultaneously, we observed that rs1682111 was associated with a decreased risk of liver cancer in the study. However, it was reported previously associated with an increased risk of breast cancer \[[@R30]\] and lung cancer \[[@R31]\]. This phenomenon may be due to the impact of SNPs on different diseases is different. Interestingly, telomere length has been associated with liver cancer risk. Therefore, *ACYP2* polymorphisms may contribute to liver cancer through impacting telomere length.

Hepatocarcinogenesis is through that the genomic changes progressively alter the hepatocellular phenotype, thereby produce cellular intermediates, and ultimately develop into liver cancer \[[@R32]\]. The pathogenesis of liver cancer is considered a multistep and complex process. Previous study has shown that HBV and HCV infection often cause hepatitis, hepatic damage, and subsequent cirrhosis, eventually initiating liver carcinogenesis \[[@R33]\]. Inflammation is also closely associated with liver cancer initiation, progression, and metastasis. Inflammatory cells by releasing chemicals to induce peripheral cell mutation, and promoting the development of liver cancer \[[@R34]\]. Carcinogens (as pesticides) can promote spontaneous initiation, cytotoxicity with sustained cell proliferation, oxidative stress, formation of activated receptors and some others to increase the risk of liver cancer \[[@R35]\]. In addition, previous reports showed that multiple genetic and epigenetic changes are involved in the molecular pathogenesis of liver cancer, for example, somatic mutations in the p53 tumor suppressor gene (*TP53*) and the activation of the WNT signal transduction pathway \[[@R33], [@R36]\]. However, the pathogenesis of liver cancer has not been elucidated completely, and need to be further explored in the future.

Our study had several limitations. First, all study participants were of the Han Chinese population and our sample size was relatively small. Second, many other risk factors including smoking and alcohol consumption were not analyzed due to a lack of corresponding clinical data. Third, we did not perform any functional analyses. Finally, because our study is the first to report associations between *ACPY2* SNPs and liver cancer, larger and more comprehensive analyses of other patient populations must be performed to confirm our results.

In conclusion, our results demonstrate that rs6713088, rs843645, rs843711, and rs843706 are associated with an increased risk of liver cancer, and that rs1682111, rs843720, and the haplotypes (ATATCGCC and CG) are associated with a decreased risk of liver cancer in the Han Chinese. Our study provides theoretical basis for the prediction of liver cancer risk and the studies on the pathogenesis of liver cancer.

MATERIALS AND METHODS {#s4}
=====================

Study participants {#s4_1}
------------------

A total of 473 patients who were diagnosed with liver cancer and admitted to the Second People\'s Hospital of Hainan Province and the Agricultural Reclamation General Hospital of Hainan Province between May 2014 and June 2015 were enrolled in the study. The control group consisted of 564 randomly selected individuals from the health examination center of the Second People\'s Hospital of Hainan Province and the Agricultural Reclamation General Hospital of Hainan Province during the same period with no history of cancer or other diseases. All patients with the diagnosis of liver cancer should be confirmed by pathological examinations. All cases were verified, and the patients were recruited without any restrictions regarding age, sex, or disease stage. All subjects were unrelated Han Chinese whose ancestors had lived in the region for at least three generations. Patients with previous history of other cancers, cancer-related treatments, surgical contraindication, pregnancy, embryo-derived tumour, active liver disease, psychiatric history or poor compliance were excluded. The study protocol was approved by the Ethics Committee of the Second People\'s Hospital of Hainan Province and Northwest University, and was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from each patient prior to participation in the study.

DNA extraction {#s4_2}
--------------

We collected 5 mL of peripheral venous blood from each participant into vacutainer tubes containing ethylene diamine tetra-acetic acid. The blood samples were stored at −80°C until use. Genomic DNA was extracted from whole blood samples using the GoldMag-Mini Whole Blood Genomic DNA Purification Kit according to the manufacturer\'s protocol (GoldMag. Co. Ltd., Xi'an, China). DNA samples were stored at −4°C for future use. DNA concentration and purity were evaluated using a spectrophotometer (NanoDrop 2000; Thermo Fisher Scientific, Waltham, MA, USA).

SNPs selection and genotyping {#s4_3}
-----------------------------

Thirteen SNPs (rs6713088, rs12621038, rs1682111, rs843752, rs10439478, rs17045754, rs843720, rs843645, rs11125529, rs12615793, rs843711, rs11896604, and rs843706) in *ACYP2* have been previously reported that are associated with several diseases and cancers risks, such as CHD \[[@R14]\], HAPE \[[@R16]\], ischemic stroke \[[@R20]\], breast \[[@R19], [@R30]\] and lung cancer \[[@R31]\], and the thirteen SNPs with a MAF \> 5% in the HapMap of the Chinese Han Beijing (CHB) population were selected for genotyping. The PCR primers for each SNP were designed using the Sequenom MassARRAY Assay Design 3.0 Software (Sequenom, San Diego, CA, USA). Genotyping was performed using the Sequenom MassARRAY platform and the manufacturer\'s protocol. Data management and analysis were performed using the Sequenom Typer 4.0 software.

Statistical analysis {#s4_4}
--------------------

All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS, version 19.0) and Microsoft Excel. The genotype frequency distribution of the 13 SNPs in the controls was analyzed for deviations from HWE using Pearson\'s chi-square tests. Age, gender, allele, and genotype frequencies were compared between the cases and groups using chi-square tests/Fisher\'s exact tests. We analyzed the associations between SNPs in *ACPY2* and the risk of liver cancer under dominant, recessive, and additive genetic models using the PLINK software. We used the Haploview software package (version 4.2) platform for analyses of pairwise LD and haplotype structure. ORs and 95% CIs were calculated using unconditional logistic regression models and adjusted for age and gender. A *P*-value \< 0.05 was considered statistically significant and all statistical tests were two-sided.

SUPPLEMENTARY MATERIALS TABLE {#s5}
=============================
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